Danish phase II trial using adipose tissue derived mesenchymal stromal cells for patients with ischaemic heart failure.

ABSTRACT:

Aims

Patients suffering from chronic ischaemic heart failure with reduced left ventricular ejection fraction (HFrEF) have reduced quality-of-life, repetitive hospital admissions, and reduced life expectancy. Allogeneic cell therapy is currently investigated as a potential treatment option after initially encouraging results from clinical autologous and allogeneic trials in patients with HFrEF. We aimed to investigate the allogeneic Cardiology Stem Cell Centre Adipose tissue derived mesenchymal Stromal Cell product (CSCC_ASC) as an add-on therapy in patients with chronic HFrEF.

Methods and results

This is a Danish multi-centre double-blinded placebo-controlled phase II study with direct intra-myocardial injections of allogeneic CSCC_ASC. A total of 81 HFrEF patients were incl

SUBMITTER: Qayyum AA 

PROVIDER: S-EPMC10053281 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature